Want to see KPRX full AI Analyst Report?
KPRX Stock Chart & Stats
$2.55
$0.05(2.00%)
At close: 4:00 PM EDT
$2.55
$0.05(2.00%)
Day’s Range― - ―
52-Week Range$1.76 - $2.95
Previous Close$2.55
Volume130.65K
Average Volume (3M)36.18K
Market Cap
$11.28M
Enterprise Value-$0.26
Total Cash (Recent Filing)$16.84M
Total Debt (Recent Filing)$333.02K
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.46
Shares Outstanding4,424,387
10 Day Avg. Volume38,148
30 Day Avg. Volume36,176
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.00Price Target Upside370.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.66
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong SolvencyVery low debt limits solvency risk and preserves financial flexibility over quarters. With only modest borrowings versus a meaningful equity base, the company can prioritize R&D spend or non-dilutive financing, supporting sustained pipeline development without immediate debt pressure.
Platform Expansion PotentialPreclinical CNS efficacy extends the ion channel platform beyond ophthalmology, meaningfully expanding addressable markets and optionality. Multi-indication potential reduces single-program dependency and can increase partnerships or licensing opportunities that support long-term commercialization pathways.
Expanded Equity Plan Aids RetentionAuthorized equity incentives strengthen the company’s ability to recruit and retain scientific and management talent critical to advancing trials. Sustained access to motivated staff supports execution of clinical programs and regulatory milestones over the coming months.
Bears Say
No Recent Revenue; Net LossesAbsence of recurring revenue and substantial net losses create dependence on external capital to sustain operations. Over multiple quarters, this undermines self-sufficiency and increases execution risk for clinical programs if financing conditions tighten or fundraising dilutes existing shareholders.
Sustained Cash BurnConsistent negative operating and free cash flow indicate the company is consuming cash to fund R&D. Persistent burn shortens runway absent financing, constraining ability to advance multiple programs concurrently and potentially forcing down-selects or delayed timelines.
Earnings Volatility / Revenue SwingLarge year-to-year swings in revenue and profitability signal unstable commercial or operational performance. This volatility complicates long-term planning, increases partner diligence hurdles, and can raise the cost of capital or limit strategic partnerships needed to scale programs.
Kiora Pharmaceuticals News
KPRX FAQ
What was Kiora Pharmaceuticals’s price range in the past 12 months?
Kiora Pharmaceuticals lowest stock price was $1.76 and its highest was $2.95 in the past 12 months.
What is Kiora Pharmaceuticals’s market cap?
Kiora Pharmaceuticals’s market cap is $11.28M.
When is Kiora Pharmaceuticals’s upcoming earnings report date?
Kiora Pharmaceuticals’s upcoming earnings report date is Nov 06, 2026 which is in 79 days.
How were Kiora Pharmaceuticals’s earnings last quarter?
Kiora Pharmaceuticals released its earnings results on Aug 07, 2026. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.47 by $0.13.
Is Kiora Pharmaceuticals overvalued?
According to Wall Street analysts Kiora Pharmaceuticals’s price is currently Undervalued.
Does Kiora Pharmaceuticals pay dividends?
Kiora Pharmaceuticals does not currently pay dividends.
What is Kiora Pharmaceuticals’s EPS estimate?
Kiora Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Kiora Pharmaceuticals have?
Kiora Pharmaceuticals has 4,424,387 shares outstanding.
What happened to Kiora Pharmaceuticals’s price movement after its last earnings report?
Kiora Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.47. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Kiora Pharmaceuticals?
Currently, no hedge funds are holding shares in KPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
KPRX Stock 12 Month Forecast
Average Price Target
$12.00
▲(370.59% Upside)
Technical Analysis
Ownership Overview
2.99% Insiders
1.05% Mutual Funds
14.13% Other Institutional Investors
81.26% Public Companies and
Individual Investors